What the early research shows

A 2005 review describes EBOO as treating up to ~4.8 L of heparinized blood in about 60 minutes with oxygen-ozone, reporting predictable changes in oxidative-stress markers and feasibility across >1,200 treatments. Authors highlighted exploratory benefits in conditions like peripheral artery disease and severe dyslipidemia, while noting the need for more rigorous trials. PubMed

In a small randomized trial in peripheral artery disease, EBOO led to greater improvement in skin lesions and symptoms versus IV prostacyclin, without reported complications across 210 sessions; arterial circulation metrics did not change, suggesting non-hemodynamic mechanisms. Results are preliminary and condition-specific. PubMed
EBOO is not FDA-approved for the treatment of any disease. Individual results vary. We do not claim to diagnose, treat, cure, or prevent disease. Research is evolving; talk to our medical team to see if EBOO is appropriate for you.

1. Mechanism Overview

EBOO (extracorporeal blood oxygenation and ozonation) is a blood-filtration technique where a patient’s blood is circulated outside the body through a device that infuses a carefully controlled oxygen–ozone gas mixture. The blood then passes through filters and is exposed to UVA and UVB light before returning to circulation.

Researchers describe the effect as a controlled oxidative stimulus:

• Small, measured amounts of oxidative stress can trigger adaptive responses.
  
• This is sometimes referred to as oxidative preconditioning, which may influence antioxidant defenses, inflammatory pathways, and redox balance .
  
  2. Practical Parameters

Early clinical reports describe:

• Volume treated: Up to ~4.8 liters of heparinized blood during a single session.
  
• Duration: Approximately 60 minutes per treatment.
  
• Frequency: Protocols varied, but multiple sessions were typically scheduled in clinical studies.
  
• Observed lab effects:
  
  Increase in lipid peroxidation markers (TBARS ↑ 4–5× immediately post-session).
  
  Reduction in protein thiols (temporary).
  
  No reported long-term depletion of antioxidant defenses .
  
  Safety Profile (Early Reports)
• Across ~1,200 EBOO sessions described in the 2005 review, treatments were generally well tolerated.
  
• In the 210-session randomized trial, no complications were reported .
  
• The authors noted the importance of strict technical control (ozone dose, blood flow rate, anticoagulation) to avoid risks.
  

Important note: Absence of reported complications in early trials does not establish safety in broader use. Modern standards still call for larger, independent studies.

4. Clinical Signals in Early Studies

Peripheral Artery Disease (PAD) – 2005 RCT

• Study design: Randomized trial comparing EBOO (105 sessions, 15 patients) vs. prostacyclin infusion (105 sessions, 15 patients).
  
• Findings:
  
  Improved symptoms & skin lesions in the EBOO group.
  
  No improvement in arterial circulation (hemodynamic measures unchanged).
  
  No complications reported during 210 sessions .
  
  
• Interpretation: Benefits may result from systemic changes (redox, inflammation, endothelial signaling) rather than direct vascular improvements.
  

Severe Dyslipidemia (Review mentions)

• Reports noted reductions in cholesterol and triglycerides following sessions, though data were uncontrolled and preliminary .
  

General Observations (Review)

• Patients often described subjective improvements in well-being.
  
• Authors emphasized the need for larger, controlled trials before definitive conclusions .
  
  5. Limitations of Current Research

• Most published work is from small, early-2000s Italian studies.
  
• Few randomized controlled trials; limited replication.
  
• Condition-specific outcomes (PAD, dyslipidemia) cannot be generalized.
  

Long-term effects are not well studied.

6. How We Use This Information at Evolve

At Evolve Anti-Aging & Wellness, we view this research as an early foundation, not a guarantee of outcomes. Here’s how it informs our approach:

• Transparency: We share available data, including both positive signals and limitations.
  
• Integration: We position EBOO as part of a broader program (metabolic optimization, mitochondrial support, recovery protocols).
  
• Monitoring: We emphasize patient safety and session-by-session assessment.
  
• Expectations: We do not claim EBOO treats or cures disease. Patients pursue EBOO with us primarily for wellness goals such as energy, recovery, and optimization.

7. References

• Di Paolo N, Bocci V, Gaggiotti E. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled oxygen-ozone administration by an extracorporeal circulation device. Int J Artif Organs. 2005;28(9):979–986. PMID: 16156950
  
• Di Paolo N, Gaggiotti E, Galli F, et al. Extracorporeal blood oxygenation and ozonation (EBOO) in patients with peripheral arterial disease: a randomized trial. Int J Artif Organs. 2005;28(10):1039–1050. PMID: 16299608
  
  Disclaimer:
  
  EBOO is not FDA-approved for the treatment of any condition. The studies above are limited, preliminary, and condition-specific. Information provided is for educational purposes only and not a substitute for medical advice.

How We Use This Evidence

1. What We Monitor

Research shows that EBOO shifts certain blood markers immediately after a session (oxidative stress and antioxidant balance). While we don’t replicate those exact lab protocols with every patient, our clinical approach mirrors the principles of safety and precision noted in the studies:

• We monitor vitals throughout the session.
  
• Our team observes tolerance and recovery closely.
  
• When clinically appropriate, we may track labs related to inflammation, oxidative stress, or recovery.
  

2. Session Parameters

Early studies described treating up to ~4.8 liters of blood over ~60 minutes using oxygen–ozone infusion with filtration and light exposure.

At Evolve, we use these publications as a framework but adapt protocols to:

• Maintain comfort and safety.
  
• Integrate session flow with adjunct therapies (IV nutrients, NAD+, Meyers cocktail, glutathione push).
  
• Allow flexibility based on patient goals and tolerance.
  

3. Safety First

• Published reports covering ~1,200 sessions showed a favorable safety profile when procedures were carefully controlled.
  
• We follow strict standards on ozone dosing, blood flow rates, and anticoagulation—parameters highlighted in the literature as critical for safety.
  
• Our medical team supervises every treatment.
  

4. Where We See the Value

The published research signals that EBOO may influence:

• Redox balance (how the body manages oxidative stress).
  
• Inflammation pathways.
  
• Metabolic factors like cholesterol and triglycerides in preliminary reports.
  

We align this with patient-centered goals, not medical claims. At Evolve, patients typically pursue EBOO for wellness outcomes such as:

• Enhanced energy and clarity.
  
• Faster recovery from stress or exertion.
  
• A sense of systemic “reset.”
  

5. Transparent Expectations

• We don’t promise specific disease outcomes.
  
• We emphasize EBOO as part of a bigger strategy: metabolic optimization, peptide support, hormone balance, and recovery nutrition.
  
• The science is promising but still early; we are transparent about what is known, what is not, and where ongoing research is heading.

How will I feel after treatment?

Many patients describe a sense of lightness, clarity, and energy after their first session. Others notice subtle changes over the next few days—better recovery, less “wired and tired,” or improved focus. Everyone responds differently, and results build over a series of sessions.

How long does a session take?

A typical session lasts about 60 minutes. This includes setup, the treatment itself, and a short recovery period.

What happens during the session?

Your blood is gently circulated outside the body, exposed to oxygen–ozone, filtered, and passed through UVA/UVB light before being returned. You’ll be comfortably reclined, monitored by our medical team the entire time.

Is it safe?

Published reports covering more than 1,000 sessions found treatments well tolerated when performed under strict technical control. At Evolve, safety is our highest priority—we carefully manage ozone dosing, blood flow, and monitoring at every step.

How many sessions do I need?

It depends on your goals. Some people feel a noticeable shift after one treatment, while others prefer a series of sessions for cumulative benefits. Our team will guide you on the best approach for you.

What makes EBOO different from a regular IV drip?

IV drips deliver nutrients into your bloodstream. EBOO, by contrast, circulates and conditions your blood itself—removing waste, infusing oxygen–ozone, and exposing it to UV light before returning it to your body. The experience is more like a full-system “reset” than a single nutrient boost.

Can I combine EBOO with other treatments?

Yes. Many patients choose to follow EBOO with IV nutrient therapy (such as NAD+, glutathione, or Meyers Cocktail) or pair it with peptide protocols for recovery and optimization. We design a sequence that supports your body’s needs.

How quickly will I notice results?

Some people notice changes right away—better energy, clearer thinking, or improved sleep quality. Others feel more gradual improvements across several treatments.

Who is EBOO for?

EBOO is ideal for people who want to support overall wellness, recovery, and performance at the cellular level. It’s not FDA-approved to treat any condition, but many pursue it as part of a proactive health and longevity plan.